Human Papillomavirus Testing in Cervical Cancer Screening

Philip E. Castle, Miriam Cremer

Research output: Contribution to journalReview articlepeer-review

11 Scopus citations


Human papillomavirus (HPV) testing is more reliable and sensitive but less specific than Papanicolaou (Pap) testing/cervical cytology for the detection of cervical precancer and cancer. HPV-negative women are at lower risk of cervical cancer than Pap-negative women. In high-resource settings, HPV testing can be used to make cervical cancer prevention programs more efficient by focusing clinical attention on women who have HPV. In lower-resource settings, where Pap testing has not been sustained or widespread, new, lower-cost HPV tests may make cervical cancer screening feasible.

Original languageEnglish (US)
Pages (from-to)377-390
Number of pages14
JournalObstetrics and Gynecology Clinics of North America
Issue number2
StatePublished - Jun 2013
Externally publishedYes


  • Cervical cancer
  • Cervical intraepithelial neoplasia
  • Human papillomavirus (HPV)
  • Low-resource settings
  • Pap testing
  • Screening
  • Vaccination
  • Visual inspection after acetic acid (VIA)

ASJC Scopus subject areas

  • Obstetrics and Gynecology


Dive into the research topics of 'Human Papillomavirus Testing in Cervical Cancer Screening'. Together they form a unique fingerprint.

Cite this